Ticker brief
NTLA INTELLIA THERAPEUTICS INC
Consumer, Non-cyclical · Biotechnology
last close
$11.21
1 day
+0.4%
14 days
-14.2%
mkt cap
$2.5B
signals 14d
19
authors 14d
8
crowd 14d
+0.8σ
Options inteloptions-surface reads · latest available day per source
| metric | reading | context |
|---|---|---|
| IV — ATM 30d | 86% mid · 35 pctile own 1y | IV/HV 1.28× (as of 2026-10-22) |
| Skew — 25Δ RR 30d | +0.051 50 pctile own 1y | balanced vs own range |
| Net dealer OI (NDOI) | +3.10 elevated | 5-session Δ +0.71 (as of 2026-07-06) |
| OI alarm | quiet | last alarm 2026-04-28 (z=2.9) |
Sentiment — last 14 days
daily mean sentiment, 2026-10-03 → 2026-10-16 · now +0.00 (−1 bearish … +1 bullish)
Who spoke8
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @harry03994688 | A | -0.16 | 6 | +0.42 |
| @cnfinancewatch | B | -1.23 | 4 | +0.36 |
| @21cshock | C | +2.21 | 2 | +0.30 |
| @BioStocks | C | -1.77 | 2 | -0.15 |
| @BPharmCatalyst | C | · | 2 | +0.00 |
| @nanalyzetweets | B | +5.59 | 1 | +0.20 |
| @eugeniodeveze | C | -3.14 | 1 | +0.40 |
| @Tautilas | C | -0.32 | 1 | +0.00 |
Recent signals19of 19 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-10-16 | @BPharmCatalyst | +0.00 | Publishes a biotech watchlist for catalysts expected in mid-winter 2026. | -1.8% | tweet ↗ |
| 2026-10-14 | @harry03994688 | +0.50 | Says a new rare-disease framework is favorable for ALNY and NTLA. | -1.9% | tweet ↗ |
| 2026-10-13 | @harry03994688 | +0.30 | Discloses holdings in RKLB, NTLA, and ALNY while noting extreme small-cap short positioning. | -5.9% | tweet ↗ |
| 2026-10-13 | @BioStocks | +0.10 | Intellia appointed Jing L. Marantz, formerly of Scholar Rock, as chief medical officer. | -5.9% | tweet ↗ |
| 2026-10-12 | @cnfinancewatch | +0.50 | Maps four listed gene-editing companies to distinct technology platforms and leadership claims. | -10.9% | tweet ↗ |
| 2026-10-12 | @harry03994688 | +0.70 | Long-form thesis says AI pressures conventional software and some biotech while favoring RNA/DNA drug companies. | -10.9% | tweet ↗ |
| 2026-10-09 | @harry03994688 | +0.50 | Presents AI-enabled biotech as a structural turnaround and highlights high-short-interest names benefiting from squeezes. | -14.2% | tweet ↗ |
| 2026-10-09 | @BPharmCatalyst | +0.00 | Six-month watchlist of upcoming PDUFA catalyst decisions; ticker list capped at six. | -14.2% | tweet ↗ |
| 2026-10-08 | @Tautilas | +0.00 | Cryptic ticker and chart-method reference requires the unseen media. | -11.0% | tweet ↗ |
| 2026-10-06 | @harry03994688 | -0.30 | Reports NTLA short interest near 40% of float and criticizes broker support for shorts. | -9.4% | tweet ↗ |
| 2026-10-06 | @eugeniodeveze | +0.40 | Reports ARK healthcare purchases and sales, including a large TWST reduction and NTLA accumulation. | -9.4% | tweet ↗ |
| 2026-10-06 | @harry03994688 | +0.80 | Forecasts a biotech short squeeze driven by AI, improving success rates and falling long-term yields. | -9.4% | tweet ↗ |
| 2026-10-06 | @BioStocks | -0.40 | Barclays initiated NTLA at Underweight with an $8 price target. | -9.4% | tweet ↗ |
| 2026-10-05 | @cnfinancewatch | +0.30 | Quantified premarket watchlist ranks breakout candidates using analyst events, flows and volume. | -12.1% | tweet ↗ |
| 2026-10-05 | @cnfinancewatch | +0.40 | Identifies bullish confluence from analyst targets, call volume, short interest, and ARK purchases. | -12.1% | tweet ↗ |
| 2026-10-03 | @21cshock | +0.30 | Reports ARK fund purchases, sales, dollar values, share counts, and portfolio-weight changes. | -8.6% | tweet ↗ |
| 2026-10-03 | @21cshock | +0.30 | Reports ARK fund purchases, sales, dollar values, share counts, and portfolio-weight changes. | -8.6% | tweet ↗ |
| 2026-10-03 | @nanalyzetweets | +0.20 | Presents genomics stocks to consider across genetic testing and gene-editing categories. | -8.6% | tweet ↗ |
| 2026-10-03 | @cnfinancewatch | +0.25 | Details ARK's prior-session purchases and their dollar amounts and ETF weights. | -8.6% | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.